SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: David Bleich who wrote (12)2/12/1998 12:41:00 PM
From: Bill Jackson  Respond to of 946
 
David; Explain?? As In understand it one product is to hopefully minimize side effects and the other targets certain cells.
If you replace a severe side effect with a minor one, I see that as a net gain. If you can selectively target certain cancer cells, another net gain. I would like a home run, but a number of small net gains add up over time.

However you're comments lack details on which to decide.

Bill



To: David Bleich who wrote (12)2/18/1998 6:49:00 PM
From: nigel bates  Read Replies (1) | Respond to of 946
 
David,

Any info on the new trial the company has announced ?
(http://biz.yahoo.com/bw/980218/cell_thera_1.html)

Nig



To: David Bleich who wrote (12)3/20/1998 4:31:00 PM
From: Stavros  Respond to of 946
 
David,
Have you ever looked at the effects of phosphodiesterase inhibitors (or other means of raising intracellular cAMP) on IL-1beta induced dysfunction of cultured rat islets? If so, are the results similar to those seen following lisofylline treatment?



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News